Aprea Therapeutics, Inc. (APRE) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on March 25, 2025, by Aprea Therapeutics, Inc., a Delaware corporation. The filing primarily serves to announce financial results for the three and twelve months ended December 31, 2024, and to disclose an amendment to an executive employment agreement.
Key Financial Metrics
The filing references a press release (Exhibit 99.1) containing the financial results for the periods ended December 31, 2024. However, the text of this Form 8-K does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. Investors must refer to the attached press release for these figures.
Material Changes and Executive Compensation
Effective March 25, 2025, the Company amended the Employment Agreement with John P. Hamill. Key changes include:
- Termination without Cause/Good Reason: Severance increased from 9 months to 12 months of base salary.
- COBRA Coverage: The Company will pay premiums for up to 12 months (increased from 9 months) following termination.
- Change of Control: If termination occurs within 12 months of a change of control, severance increases to 18 months of base salary and COBRA coverage.
Outlook, Risks, and Other Events
The Company updated its corporate presentation slide deck on March 25, 2025, which is filed as Exhibit 99.2. The filing explicitly states that the financial information and press release are not deemed "filed" under Section 18 of the Exchange Act and are not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific revenue, cash burn, and liquidity figures for the year ended December 31, 2024.
- Verify the full text of the amended Employment Agreement with John P. Hamill, which will be filed in the upcoming Form 10-K.
- Examine Exhibit 99.2 (Corporate Presentation) for updated operational milestones and strategic outlook.
- Confirm the Company's cash runway based on the Q4 2024 results to assess funding needs.